OrbiMed Backs Nucleus RadioPharma with $50M to Scale Radioligand Therapy Production

Nucleus RadioPharma, a contract development and manufacturing organization specializing in radioligand therapies, has secured $50 million in financing from OrbiMed, the healthcare-focused investment firm announced Monday. The deal — structured as an exclusive arrangement with the New York-based investor — will fund a multi-site expansion of production capacity as the nascent radioligand therapy market barrels toward commercialization.

The investment comes as pharmaceutical giants including Novartis, Eli Lilly, and AstraZeneca pour billions into radioligand therapies, a precision oncology approach that uses radioactive isotopes to deliver targeted radiation directly to cancer cells. Unlike traditional chemotherapy, which floods the body with toxic agents, radioligands bind to specific receptors on tumor surfaces — killing malignant cells while largely sparing healthy tissue.

But there's a problem: almost no one can make these drugs at scale yet. Radioligand manufacturing requires specialized facilities with lead-lined walls, decay management systems, and just-in-time logistics — the isotopes used in these therapies have half-lives measured in hours or days, not months. That production bottleneck is exactly what Nucleus RadioPharma and OrbiMed are betting $50 million they can solve.

"The radioligand therapy space is at an inflection point," said Jonathan Silverstein, a partner at OrbiMed who will join Nucleus RadioPharma's board as part of the deal. "You have multiple Phase 3 programs reading out, regulatory approvals accelerating, and essentially zero contract manufacturing capacity that can handle the complexity and speed these products demand." Silverstein declined to specify OrbiMed's equity stake or valuation but confirmed the financing is structured as preferred equity with expansion milestones tied to additional capital deployment.

To understand why Nucleus RadioPharma is raising this kind of money, you have to understand what makes radioligand production different from traditional pharmaceutical manufacturing. Standard small-molecule drugs can be made in bulk, stored for years, and shipped globally without time pressure. Radioligands can't.

The active ingredients — isotopes like lutetium-177, actinium-225, or iodine-131 — decay predictably. Lutetium-177, used in Novartis' FDA-approved Pluvicto for prostate cancer, has a half-life of 6.6 days. That means a batch loses half its potency in under a week. Actinium-225, the next-generation isotope multiple companies are racing to deploy, decays in 10 days. You can't stockpile inventory. You can't manufacture in Asia and ship to the U.S. You produce close to the patient and you move fast.

Then there's the facility complexity. Radioligand production requires hot cells — shielded enclosures where isotopes are handled remotely — along with ventilation systems that manage radioactive decay gases and waste streams. Staff need radiation safety training. Equipment requires constant calibration. Regulatory oversight is intense, involving both FDA drug manufacturing standards and Nuclear Regulatory Commission protocols.

All of this makes the sector highly capital-intensive and deeply specialized. According to a 2024 report from Evaluate Pharma, the global radioligand therapy market is projected to reach $12 billion by 2030, up from just $1.2 billion in 2023 — but manufacturing capacity is expected to lag demand by at least three years unless significant new facilities come online soon.

Founded in 2017 and headquartered in Miami, Florida, Nucleus RadioPharma operates as a CDMO — contract development and manufacturing organization — focused exclusively on radioligand therapies. The company doesn't develop its own drugs. Instead, it partners with biotech and pharma companies that need someone to handle the messy, expensive work of turning a promising radioligand candidate into a manufacturable, distributable product.

Nucleus currently operates production facilities in Miami and has partnerships with radiopharmacies and isotope suppliers across North America. The $50 million will fund three major initiatives, according to the company: expanding its Miami headquarters with additional hot cell capacity, opening at least one new regional manufacturing hub in the U.S., and building out cold chain logistics infrastructure to handle distribution.

The company also plans to invest heavily in automation and process optimization. Right now, most radioligand manufacturing is semi-manual — highly trained technicians perform batch production steps inside hot cells using remote manipulators. Nucleus wants to automate more of that workflow, both to increase throughput and reduce human error. "We're seeing clients come to us with Phase 3 assets that could be on the market in 18 months, and they need a manufacturing partner that can go from tech transfer to commercial-scale production in that window," said Dr. Miguel Barboza, CEO of Nucleus RadioPharma, in a statement. "This financing gives us the capital to build that capacity ahead of demand, not in reaction to it."

Barboza, a radiochemist by training, previously worked at Lantheus Medical Imaging, one of the few publicly traded companies in the radiopharmaceutical space. He declined to disclose Nucleus RadioPharma's current client roster or revenue, citing confidentiality agreements, but confirmed the company is working with both large-cap pharmaceutical companies and clinical-stage biotech firms.

The company is evaluating potential sites in the Midwest and Northeast for its next facility, with a target opening date in late 2026. The goal is to create a distributed manufacturing network that can serve patients within 24 hours of production — critical given isotope decay timelines. Nucleus is also exploring partnerships with hospital-based radiopharmacies to handle last-mile distribution and dose preparation.

Nucleus RadioPharma isn't entering an empty market. The radioligand therapy sector has been heating up rapidly since Novartis won FDA approval for Pluvicto in March 2022, followed by Lutathera for neuroendocrine tumors. Those two drugs alone generated over $1.3 billion in combined sales in 2023, according to Novartis' annual report.

Eli Lilly paid $1.4 billion to acquire Point Biopharma in 2023, gaining access to a pipeline of lutetium-based radioligands targeting prostate and breast cancer. AstraZeneca and Bristol Myers Squibb have both inked multi-billion-dollar licensing deals for radioligand candidates. Smaller players like RayzeBio (acquired by BMS for $4.1 billion in late 2023) and Fusion Pharmaceuticals (acquired by AstraZeneca for $2.4 billion in 2024) have been snapped up at premium valuations.

But very few of those companies — or their acquirers — have in-house manufacturing capacity for radioligands. Most are contracting out production to a tiny handful of specialized CDMOs. That's where Nucleus RadioPharma sees its opening.

The competitive landscape for radioligand manufacturing includes established players like SOFIE (a subsidiary of Jubilant Pharma), Cardinal Health's radiopharmaceutical division, and Curium Pharma, a European leader in the space. Each has decades of experience in nuclear medicine, but most of their infrastructure was built for diagnostic imaging agents — not therapeutic radioligands, which require higher purity standards and more complex formulations.

That legacy infrastructure gap is part of why new, therapy-focused CDMOs like Nucleus are attracting capital. They're building facilities designed from the ground up for the next generation of radioligands, including alpha-emitting isotopes like actinium-225, which are far more potent than the beta-emitters currently on the market but also harder to handle safely.

One of the thorniest challenges facing the radioligand sector isn't just manufacturing capacity — it's isotope supply. Actinium-225, the isotope seen as the future of radioligand therapy due to its potency, is currently produced in tiny quantities globally. Most supply comes from decay of legacy uranium-233 stockpiles or small-scale accelerator production. Multiple companies, including Fusion and Orano Med, are working to scale up production, but supply constraints remain a major bottleneck.

Nucleus RadioPharma hasn't disclosed whether its expansion plans include backward integration into isotope production, but the company confirmed it has "strategic partnerships" with multiple isotope suppliers to secure feedstock for client programs. That supply chain coordination — ensuring isotopes arrive at the production facility at the right time, in the right quantity, with the right purity — is as critical as the manufacturing itself.

OrbiMed, with over $17 billion in assets under management, has been one of the most active investors in the life sciences sector for two decades. The firm has backed everything from early-stage biotech to late-stage med-tech to healthcare services platforms. This deal fits a pattern: OrbiMed often invests in infrastructure plays that benefit from broader sector tailwinds without being tied to the success of any single drug.

Backing a CDMO is a classic picks-and-shovels strategy. Even if individual radioligand drugs fail in clinical trials, the companies developing them still need manufacturing capacity to get to that failure point. And if the sector grows as projected, demand for contract manufacturing will outstrip supply for years.

"We don't have to pick the winning drug," Silverstein said. "We're betting on the category — and on the thesis that manufacturing capacity will be the limiting factor for this market's growth over the next five to seven years." OrbiMed's investment is structured to scale with Nucleus RadioPharma's facility expansion, with milestone-based tranches tied to new site openings and production volume targets, though specific terms weren't disclosed.

The firm has a track record in this space. OrbiMed previously invested in Alcami, a CDMO acquired by Carlyle Group, and has backed multiple biotech companies developing radioligand therapies, giving it a layered exposure to the sector's growth.

For the dozens of biotech companies currently advancing radioligand candidates through clinical trials, the Nucleus RadioPharma expansion is critical infrastructure. Many of these companies are pre-revenue, burning cash on R&D, and can't afford to build their own manufacturing facilities. Outsourcing production to a CDMO is the only viable path to market — but only if capacity exists when they need it.

The challenge is timing. A Phase 3 trial might read out in 2026, with potential FDA approval in 2027. But if a CDMO can't commit to commercial-scale production capacity until 2028, that company faces a painful choice: delay its launch, accept severe supply constraints, or try to build its own facility at enormous cost and risk. Nucleus RadioPharma's bet is that companies will pay a premium to lock in capacity now, even if they won't need it for 18-24 months.

One reason there aren't more players in radioligand manufacturing is the regulatory complexity. Facilities must comply with FDA current good manufacturing practice (cGMP) standards for drug production, Nuclear Regulatory Commission licensing for handling radioactive materials, and state-level radiation safety rules. Getting all three approvals for a single facility can take 18-24 months and cost tens of millions of dollars before a single dose is produced.

That's a barrier to entry. But for companies already navigating it successfully, it's also a moat. Once you have regulatory approval, trained staff, and validated processes, replicating that infrastructure is expensive and slow for competitors. Nucleus RadioPharma's existing facilities and regulatory track record give it a head start in the race to scale.

The company is also investing in regulatory consulting services for clients — helping them design manufacturing processes that meet FDA standards from the start, rather than retrofitting after Phase 2. "A lot of academic labs and early-stage biotechs develop these compounds in ways that are never going to scale to commercial production," Barboza said. "We're trying to insert ourselves earlier in the development process to avoid costly redesigns later."

That early engagement model could differentiate Nucleus from larger, more transactional CDMOs — though it also requires the company to take on more technical risk and longer sales cycles.

The bull case for radioligand therapy is straightforward: multiple Phase 3 trials are succeeding, the drugs work in patient populations with few other options, and oncologists are beginning to understand how to sequence these therapies with other treatments. If the current pipeline converts at historical rates, the sector could see 8-10 FDA approvals by 2030, supporting the $12 billion market projection.

The bear case is harder to dismiss. Radioligands are expensive — Novartis' Pluvicto costs around $42,500 per dose, with patients typically receiving multiple doses. Reimbursement remains a question mark outside of late-line metastatic cancer settings. Manufacturing costs are high and unlikely to drop dramatically even with scale. And isotope supply constraints, particularly for actinium-225, could throttle growth regardless of manufacturing capacity.

Nucleus RadioPharma and OrbiMed are clearly banking on the bull case, but the company's expansion strategy suggests awareness of these risks. By building a distributed network rather than betting everything on a single mega-facility, Nucleus reduces geographic concentration risk and creates optionality to serve different client needs across regions.

The focus on automation and process optimization also signals an attempt to drive down per-dose manufacturing costs over time, which could become a competitive advantage if reimbursement pressure intensifies and clients start demanding lower contract manufacturing fees.

There's a scenario where $50 million turns out to be too little, too late. If radioligand therapies start moving into earlier treatment lines — first-line metastatic cancer, or even adjuvant settings post-surgery — patient volumes could explode. Evaluate Pharma's $12 billion projection assumes radioligands remain largely confined to late-stage, heavily pre-treated patients. If that assumption breaks, demand could double or triple.

In that scenario, every CDMO in the space would be supply-constrained, and pricing power would shift heavily toward manufacturers. Nucleus RadioPharma's current buildout would position it well — but it would also likely need to raise significantly more capital to keep pace. OrbiMed's structure, with milestone-based tranches, suggests the firm is prepared for that possibility.

The flip side: if adoption is slower, or if manufacturing technology improves faster than expected (making it easier for pharma companies to bring production in-house), CDMOs could face margin compression and utilization challenges. Nucleus is making a calculated bet that the next three to five years belong to the outsourced model — but that window won't stay open forever.

Silverstein acknowledged the timing risk but argued it's manageable. "We're not trying to build a business that lasts forever," he said. "We're trying to build the dominant contract manufacturer for the next wave of radioligand therapy approvals. Whether that's a 10-year run or a 20-year run, the market opportunity in front of us right now justifies the capital deployment."

The $50 million Nucleus RadioPharma raise is notable not just for its size but for its structure. Most recent capital raises in the radioligand space have gone to drug developers, not infrastructure providers. When CDMOs do raise capital, it's typically through private equity buyouts or corporate acquisitions, not growth equity from specialist healthcare investors.

OrbiMed's exclusive financing model — where the firm is the sole capital provider rather than one participant in a syndicated round — gives it significant influence over Nucleus RadioPharma's strategic direction and future exit options. That's a trade-off: the company gets faster capital and a highly engaged partner, but also cedes more control than it would in a traditional Series A or B with multiple VCs.

The deal also positions Nucleus RadioPharma as a potential acquisition target down the line. If a major pharmaceutical company decides it needs in-house radioligand manufacturing, buying an established CDMO with facilities, regulatory approvals, and client relationships is faster and lower-risk than building from scratch. OrbiMed has a long track record of backing companies to a strategic exit, and the radioligand sector's M&A velocity suggests that pathway is plausible.

For now, though, Barboza and Silverstein both said the focus is on execution, not exit. "We have Line of sight to being the largest independent radioligand CDMO in North America within 24 months," Barboza said. "That's the goal. Everything else is downstream from that."

The Nucleus RadioPharma financing raises as many questions as it answers. The company didn't disclose its current revenue, profitability, or client count — all of which would help contextualize whether $50 million is adequate or just the first of multiple rounds. The timeline for new facility openings is vague ("late 2026" for the second site, with no specifics on location or capacity). And the isotope supply strategy remains opaque.

Observers should track several key milestones over the next 12-18 months. First, whether Nucleus announces a specific site selection and regulatory filing for its second facility — that would signal the company is moving from capital raise to capital deployment. Second, whether any major pharmaceutical companies publicly announce manufacturing partnerships with Nucleus, which would validate the market demand thesis. Third, whether Nucleus begins offering services for actinium-225-based therapies, which would indicate the company has solved critical supply and handling challenges.

More broadly, the radioligand therapy sector is entering a critical phase. The next 18 months will see multiple Phase 3 readouts, several potential FDA approvals, and the first real stress test of manufacturing capacity. If Nucleus RadioPharma and its peers can scale successfully, the sector's growth trajectory stays intact. If capacity bottlenecks emerge, expect delays, price spikes, and potentially a wave of M&A as pharma companies scramble to secure supply.

OrbiMed's $50 million bet is that Nucleus RadioPharma can stay ahead of that curve. Whether that proves right depends on execution, timing, and variables — isotope supply, regulatory speed, clinical trial results — that no amount of capital can fully control. But in a market where the infrastructure doesn't exist yet and the demand is coming fast, being early and well-funded is a decent place to start.